Media stories about AcelRx Pharmaceuticals (NASDAQ:ACRX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AcelRx Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 46.4836140555564 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Several equities research analysts recently commented on ACRX shares. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of AcelRx Pharmaceuticals in a report on Friday, October 27th. Roth Capital set a $8.00 price target on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, October 12th. Royal Bank Of Canada set a $6.00 price target on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 25th. Stifel Nicolaus raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Finally, Jefferies Group lowered shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 13th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $6.83.

Shares of AcelRx Pharmaceuticals (NASDAQ ACRX) opened at $2.20 on Tuesday. AcelRx Pharmaceuticals has a 1-year low of $1.55 and a 1-year high of $5.75. The company has a debt-to-equity ratio of -0.43, a quick ratio of 4.71 and a current ratio of 4.78.

In other AcelRx Pharmaceuticals news, Director Mark G. Edwards bought 30,000 shares of the company’s stock in a transaction dated Tuesday, November 14th. The stock was acquired at an average price of $1.90 per share, with a total value of $57,000.00. Following the completion of the acquisition, the director now directly owns 150,000 shares of the company’s stock, valued at $285,000. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Lawrence G. Hamel sold 10,161 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $5.29, for a total transaction of $53,751.69. Following the sale, the insider now directly owns 16,379 shares of the company’s stock, valued at approximately $86,644.91. The disclosure for this sale can be found here. Insiders have bought 42,000 shares of company stock valued at $89,380 in the last ninety days. Insiders own 28.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “AcelRx Pharmaceuticals (ACRX) Earns Media Sentiment Score of 0.14” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://theolympiareport.com/2017/12/05/acelrx-pharmaceuticals-acrx-earns-media-sentiment-score-of-0-14.html.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Insider Buying and Selling by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.